公开(公告)号：US20250019675A1

公开(公告)日：2025-01-16

申请号：US18684923

申请日：2022-08-30

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Brent M. DORR ,  Joel MELBY ,  Deepak RUDRAPPA ,  Jeliazko JELIAZKOV ,  Nilesh VAIDYA

IPC: C12N9/12 ,  C12P19/34

Abstract: The present disclosure provides T7 RNA polymerase variants, the use of which increases transcription efficiency and improves the quality and yield of the enzyme. Also provided are polynucleotides encoding the T7 RNA polymerase variants, host cells capable of expressing the T7 RNA polymerase variants, and methods of using the T7 RNA polymerase variants for high-efficiency transcription.

公开(公告)号：US12186389B2

公开(公告)日：2025-01-07

申请号：US18494893

申请日：2023-10-26

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Benjamin Petsch ,  Dominik Vahrenhorst ,  Diego Chaves Moreno ,  Janina Gergen ,  Jessica Michelle Devant ,  Kristina Kovacikova ,  Hans Wolfgang Große

IPC: A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  C07K14/165 ,  A61K39/00

Abstract: The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.

公开(公告)号：US20240352496A1

公开(公告)日：2024-10-24

申请号：US18687892

申请日：2022-08-29

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Justin Ross HALMAN ,  Nilesh VAIDYA

IPC: C12P19/34

CPC classification number: C12P19/34

Abstract: Improved methods for manufacturing a RNA by IVT and compositions for use therein are provided.

公开(公告)号：US20240239845A1

公开(公告)日：2024-07-18

申请号：US18596426

申请日：2024-03-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Andrea CARFI

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  A61K2039/53 ,  C07K2319/735 ,  C12N2760/18522 ,  C12N2760/18534

Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

公开(公告)号：US20240216276A1

公开(公告)日：2024-07-04

申请号：US18225749

申请日：2023-07-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew GEALL ,  Ayush VERMA

IPC: A61K9/127 ,  A61K9/00 ,  A61K9/10 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  C12N15/88

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/1271 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  C12N15/88 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/55555 ,  C12N2710/16134 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2770/36171

Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer campuses at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1 kDa and 3 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

公开(公告)号：US20240181037A1

公开(公告)日：2024-06-06

申请号：US18283601

申请日：2022-03-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA ,  CUREVAC SE

Inventor： Hans Wolfgang GROßE ,  Edith JASNY ,  Janine MÜHE ,  Ventzislav Bojidarov VASSILEV ,  Clarisse LORIN ,  Nadia OUAKED ,  Corey MALLETT ,  Ronan ROUXEL ,  Normand BLAIS

IPC: A61K39/145 ,  A61K39/00 ,  A61P31/16 ,  A61P37/04

CPC classification number: A61K39/145 ,  A61P31/16 ,  A61P37/04 ,  A61K2039/53 ,  A61K2039/6018 ,  A61K2039/6031 ,  A61K2039/6093

Abstract: The present invention relates to carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.

公开(公告)号：US11986518B2

公开(公告)日：2024-05-21

申请号：US16985979

申请日：2020-08-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Christiane Gerke ,  Laura Bartle Martin ,  Allan James Saul

IPC: A61K39/112 ,  A61K39/00

CPC classification number: A61K39/0283 ,  A61K2039/55505 ,  A61K2039/55572 ,  A61K2039/70 ,  Y02A50/30

Abstract: This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.

公开(公告)号：US20240132550A1

公开(公告)日：2024-04-25

申请号：US18328162

申请日：2023-06-01

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Maria SCARSELLI ,  Daniele VEGGI

IPC: C07K14/22 ,  A61K39/095 ,  A61P31/04

CPC classification number: C07K14/22 ,  A61K39/095 ,  A61P31/04 ,  C07K2319/00

Abstract: The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing against Neisseria meningitidis infection.

公开(公告)号：US11959092B2

公开(公告)日：2024-04-16

申请号：US16635352

申请日：2018-08-07

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Amirreza Faridmoayer ,  Michael Thomas Kowarik ,  Gerd Martin Lipowsky ,  Fabio Serventi

IPC: C12N9/00 ,  C12N9/10 ,  C12N15/90

CPC classification number: C12N15/902 ,  C12N9/1048 ,  C12N9/1051 ,  C12N2800/24 ,  C12N2800/30

Abstract: The present invention discloses a process for engineering a host cell comprising the steps of; a) integrating a first polynucleotide cassette including a first selection marker flanked by a first pair of recombination sites; b) removing the first selection marker by the action of a recombinase which recognises the first pair of recombination sites; c) integrating a second polynucleotide cassette including a second selection marker flanked by a second pair of recombination sites; and d) removing the second selection marker by the action of a recombinase which recognises the second pair of recombination sites. Also disclosed is a host cell genome polynucleotide comprising a first recombinantly engineered region and a second recombinantly engineered region, wherein a first single recombination site is adjacent to the first recombinantly engineered region, and a second single recombination site is adjacent to the second recombinantly engineered region.

公开(公告)号：US11944675B2

公开(公告)日：2024-04-02

申请号：US17061687

申请日：2020-10-02

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Fabiana Fernandez ,  Michael Kowarik ,  Michael Wacker ,  Michael Wetter

IPC: A61K39/112 ,  A61K39/00 ,  A61K39/02 ,  A61K39/104 ,  A61K39/108 ,  A61K39/385 ,  C07K14/195

CPC classification number: A61K39/0283 ,  A61K39/0258 ,  A61K39/104 ,  A61K39/105 ,  A61K39/385 ,  C07K14/195 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6087 ,  C07K2319/034 ,  Y02A50/30

Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.